Novozymes


Soft Q2, FY 19 guidance now looks challenging

13/08/19 -"Novozymes reported soft Q2 19 numbers – missing street consensus but meeting our estimates. Sales were down 2% on an organic basis – driven by Agriculture & Feed and Food & ..."

Pages
56
Language
English
Published on
13/08/19
You may also be interested by these reports :
16/08/19
Our last Novozymes (Add, Denmark) Teaser was aptly titled, ‘Crude-driven Novozymes’. That proved right, again and sadly on the way down. This, in ...

14/08/19
Hikma reported a strong performance in H1 19, with revenue growth of 8% (at CER), primarily attributable to a better-than-expected performance of ...

13/08/19
Novozymes reported soft Q2 19 numbers – missing street consensus but meeting our estimates. Sales were down 2% on an organic basis – driven by ...

13/08/19
Solid momentum of the new drugs, Ozempic and Saxenda, helped Novo Nordisk achieve another healthy quarterly performance, while the insulin woes only ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO